Literature DB >> 15017387

E2FBP1/hDril1 modulates cell growth through downregulation of promyelocytic leukemia bodies.

Y Fukuyo1, K Mogi, Y Tsunematsu, T Nakajima.   

Abstract

Promyelocytic leukemia nuclear bodies (PML-NBs) comprise multiple regulatory factors and play crucial roles in the maintenance of cellular integrity, while unregulated activation of PML-NBs induces death and premature senescence. Hence, the function of PML-NBs must be directed properly; however, the mechanism that regulates PML-NBs remains unclear. In this paper, we show that PML-NBs are disintegrated by an AT-rich interaction domain family protein E2FBP1/hDril1 through specific desumoylation of promyelocytic leukemia protein (PML) in vivo and in vitro. RNA interference-mediated downregulation of E2FBP1/hDril1 results in hyperplasis of PML-NBs and consequent commitment to PML-dependent premature senescence. Thus, the function of E2FBP1/hDril1 is required for maintenance of survival potential of the cells. Our data suggest a novel mechanism to govern cellular integrity through the modulation of nuclear depots.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017387     DOI: 10.1038/sj.cdd.4401412

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  10 in total

1.  A regulated nucleocytoplasmic shuttle contributes to Bright's function as a transcriptional activator of immunoglobulin genes.

Authors:  Dongkyoon Kim; Philip W Tucker
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 2.  The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1.

Authors:  Shuai Wang; Jing Long; Chun-fu Zheng
Journal:  Protein Cell       Date:  2012-04-28       Impact factor: 14.870

3.  The herpes simplex virus immediate-early ubiquitin ligase ICP0 induces degradation of the ICP0 repressor protein E2FBP1.

Authors:  Yayoi Fukuyo; Nobuo Horikoshi; Alexander M Ishov; Saul J Silverstein; Takuma Nakajima
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

4.  Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells.

Authors:  Jamee C Nixon; Scott Ferrell; Cathrine Miner; Athenia L Oldham; Ute Hochgeschwender; Carol F Webb
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

5.  Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells.

Authors:  Michelle L Ratliff; Julie M Ward; Joan T Merrill; Judith A James; Carol F Webb
Journal:  J Immunol       Date:  2014-12-22       Impact factor: 5.422

Review 6.  The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis.

Authors:  Michelle L Ratliff; Troy D Templeton; Julie M Ward; Carol F Webb
Journal:  Front Immunol       Date:  2014-03-19       Impact factor: 7.561

Review 7.  The Role of LIN28-let-7-ARID3B Pathway in Placental Development.

Authors:  Asghar Ali; Gerrit J Bouma; Russell V Anthony; Quinton A Winger
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

8.  SUMOylation of DRIL1 directs its transcriptional activity towards leukocyte lineage-specific genes.

Authors:  Alexandre Prieur; Karim Nacerddine; Maarten van Lohuizen; Daniel S Peeper
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

9.  Analysis of the SUMO2 Proteome during HSV-1 Infection.

Authors:  Elizabeth Sloan; Michael H Tatham; Marine Groslambert; Mandy Glass; Anne Orr; Ronald T Hay; Roger D Everett
Journal:  PLoS Pathog       Date:  2015-07-22       Impact factor: 7.464

Review 10.  Recent advances in the ARID family: focusing on roles in human cancer.

Authors:  Chen Lin; Wei Song; Xinyu Bi; Jianjun Zhao; Zhen Huang; Zhiyu Li; Jianguo Zhou; Jianqiang Cai; Hong Zhao
Journal:  Onco Targets Ther       Date:  2014-02-18       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.